rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AAPG
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Ascentage Pharma's Lisaftoclax Granted China Breakthrough Designation
      Oct 21Yahoo FinanceAAPG
      Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
      Oct 20Yahoo FinanceAAPG
      Ascentage Pharma (SEHK:6855) Stock Looks Above Fair Value After The Fall

      Ascentage Pharma Group International has seen its share price move sharply in recent years, yet the current level still leaves a straightforward question for investors who care about fundamentals. Is the price you see on screen today reasonably aligned with what the business is generating in sales, or has sentiment moved further than the top line can comfortably support? With the stock down 56.4% over the past year, the slide puts fresh focus on whether the present valuation can still be...

      Oct 19Yahoo FinanceAAPG
      Ascentage Pharma Stock Could More Than Double: Analyst - Ascentage Pharma Group (NASDAQ:AAPG)

      William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.

      Oct 16BenzingaAAPG
      Citizens initiates Ascentage Pharma stock with outperform rating
      Oct 13Investing.comAAPG
      3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
      Oct 10Yahoo FinanceAAPGIVA
      Ascentage Pharma to Participate in Four Upcoming Investor Conferences

      ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in four upcoming investor conferences in New York, New York. Citi’s 2026 Biopharm

      Sep 2Yahoo FinanceAAPG
      Ascentage Pharma Group International (SEHK:6855) Could Be 18% Undervalued After Half Year Losses

      Half year earnings put Ascentage Pharma Group International (SEHK:6855) losses in focus Ascentage Pharma Group International (SEHK:6855) released half year earnings to June 30, 2026, reporting sales of CNY 302.21 million and a net loss of CNY 816.69 million, with a basic loss per share of CNY 2.19. Ascentage Pharma Group International’s recent half year results arrived alongside a sharp move in the stock, with a 1 day share price return of 12.08% and a 7 day share price return of 9.88% at...

      Aug 28Yahoo FinanceAAPG
      Ascentage Pharma Earnings Call Highlights Pipeline Momentum

      Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.

      Aug 24The Globe and MailAAPG
      ASCENTAGE PHARMA GROUP INTERNATIONAL Q2 2026 Earnings Call Summary

      Moby summary of ASCENTAGE PHARMA GROUP INTERNATIONAL's Q2 2026 earnings call

      Aug 21Yahoo FinanceAAPG
      Transcript: Ascentage Pharma Group H1 2026 Earnings Conference Call
      Aug 21BenzingaAAPG

      This is the newest page. Registered accounts read further back.